GT-Plex™ BCR-ABL Fusion Panel
Identify ten BCR-ABL fusion types and a wild-type BCR-ABL target within a single well using our patent-pending multiplexed digital PCR (dPCR) technology (RUO). BCR-ABL fusions are present in approximately 95% of chronic myeloid leukemia (CML) cases and 20% of acute lymphoblastic leukemia (ALL) cases. While major (e14a2/e13a2) and minor (e1a2) fusion types are most common in CML and ALL, respectively, rare fusion types also exist and have prognostic and therapeutic impact. Molecular monitoring of BCR-ABL transcript levels at various stages of treatment provides insight into future outcomes. For example, research has shown that BCR-ABL levels > 10% at 6 months or > 1% at 12 months on tyrosine kinase inhibitor (TKI) therapy is indicative of treatment failure and associated with poor progression-free survival. Request our application note for further background and information.
Research Use Only (RUO). Not intended for diagnostic purposes. Contact us for assay kit availability on more platforms!
BCR-ABL Fusion Detection Panels for the Roche Digital LightCycler® System
- Highly multiplexed assay measures ten (10) BCR-ABL mutations in a single well
- Patent-pending technology allows for highly specific detection and quantification
- Kits include controls and step-by-step data analysis guidance
- Assay detects key BCR-ABL fusions in RNA even in very low concentration blood samples
GT-Plex™ Multiplexed BCR-ABL Panel
BCR-ABL Translocation Fusion Targets in One Assay Solution
- Major: e13a2, e13a3, e14a2, e14a3
- Minor: e1a2, e1a3
- Micro: e19a2, e19a3
- Nano: e6a2, e6a3
Controls Included
One ABL1 positive control, and positive controls for each fusion type (e14a2, e1a2, e19a2, and e6a2).
Highly Sensitive
Detect as few as 3 target copies per reaction
Robust
Eliminate interference from PCR inhibitors compared to real-time quantitative PCR (RT-qPCR)
High Throughput
Multiplex for faster throughput and lower reagent cost
Compatible
Use with RNA from bone marrow and whole blood samples
GT-Plex™ Multiplex Digital PCR Assays Show Robust Performance Across a Broad Linear Dynamic Range
Our BCR-ABL Oncology Assays Are Optimized for the Roche Digital PCR Platform with More in Development!
Key Benefits
Detect as few as 3 copies of the BCR-ABL gene targets per reaction and genotype samples with low nucleic acid concentrations
Leverage our GT-Plex™ technology to amplify more targets in each assay, saving you time and money
Assay your samples with validated kits that include all necessary primers, probes, and controls
Minimize interference from PCR inhibitors using dPCR technology
Popular Oncology Research Kits
Quantify Your Target in 3 Easy Steps
Receive kit via overnight shipping within five business days
Extract nucleic acid from your sample using your lab’s preferred method
Perform the PCR assay on your sample using your instrument of choice
GT Molecular dPCR Assay Advantages
FAQs
